Sumitomo Pharma Co (FRA:DPM) Net Income From Continuing Operations : €-1,739 Mil (TTM As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Sumitomo Pharma Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sumitomo Pharma Co's net income from continuing operations for the three months ended in Sep. 2024 was €-304 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was €-1,739 Mil.

Sumitomo Pharma Co Net Income From Continuing Operations Historical Data

The historical data trend for Sumitomo Pharma Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Net Income From Continuing Operations Chart

Sumitomo Pharma Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

301.91

284.61

310.89

-675.80

-1,933.90

Sumitomo Pharma Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-183.00	-318.21	-1,211.14	93.78	-303.57

Sumitomo Pharma Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,739 Mil.

Sumitomo Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (FRA:DPM) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

DNPUF:USA 4506:Japan DPM:Germany

Address

6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045

Website

https://www.sumitomo-pharma.com

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.